Compare National Beverage Corp. (FIZZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Novavax Inc — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.89B), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: National Beverage Corp. is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Novavax Inc for 59 Days on average.
| FIZZ | NVAX | |
|---|---|---|
Market Cap | $2.89B | $1.82B |
Volume | 553,950 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $12.56 |
52-Week Low | $29.20 | $6.22 |
Typical Hold Time | 33 Days | 59 Days |
Enterprise Value | $2.84B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals. The company reported stagnant $1.2B revenue but improved net margins to 15.55% in 2025. Recent earnings misses and a $3.25 special dividend highlight mixed performance. Technical indicators show strong bearish momentum with support at $29 and resistance at $30.
Outlook remains challenged by margin pressure and growth stagnation. While strong profitability metrics (40% ROE) provide support, analyst sentiment is cautious with 50% sell ratings. Key risks include competitive pressures and input cost inflation affecting gross margins.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
